On May 26, the PUMCH prospective intervention study of osteoporotic re-fractures (Sequential Therapy with Teriparatide and Denosumab, STAND study) enrolled the first patient, marking essential strides in a major project led by Xia Weibo, Director of the Depart...

Recently, the PUMCH ophthalmology team led by Professor Zhang Meifen published an original article titled “Cerebrospinal Fluid Interleukin-10 Biomarker for Vitreoretinal Lymphoma” in the “American Journal of Ophthalmology” (Q1, ranked among top 5% journals acc...

On June 9, a meeting between PUMCH, Guizhou Provincial Health Commission and the Affiliated Hospital of Zunyi Medical University was held online. Du Bin, Vice President of PUMCH, and Xiao Minglong, a leader at the level of Deputy Director-General from Guizhou ...

On June 2, the phase I/II clinical trial of GC301 adeno-associated virus (AAV) injection (“GC301 injection”), a gene therapy drug for infantile-onset Pompe disease, were launched at Peking Union Medical College Hospital (PUMCH). GC301 injection, the China-deve...